双美生物科技股份有限公司 Approved
最後更新時間 2025/08/03 , 05:30 PM
最後更新時間 2025/08/03 , 05:30 PM
負責人
Lin,Qi-Guo
統一編號
12744147
成立日期
2001/02/06
資本額
NT$680,000,000
實收資本額
NT$544,630,000
股票代號
4728
電話
06-5053288
地址
1F, No. 10, Ln. 31, Sec. 1, Huandong Rd., Xinshi Dist., Tainan City, 744, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Lin,Qi-Guo Chairman 0.94% HE XIN INVESTMENT CO., LTD.
Yang,Yan-Ji Vice Chairman 1.38%
GINKO OPTICAL INDUSTRIAL CO., LTD. Director 0.01%
Lin,Jin-Han Director 1.70%
XIU QI Co., Ltd. Director 0.97%
KUO TUNG INTERNATIONAL CO., LTD. Director 0.01%
GUANG XUE Co., Ltd. Director 0.95%
MING ZHI INTERNATIONAL CO., LTD. Director 0.01%
LXY TECHNOLOGY CO., LTD. Director 0.00%
LONG TAN QIAN GAS LTD. Director 0.00%
WEN MEI GLOBAL INVESTMENT CO., LTD. Director 0.00%
MEI LIN GLOBAL INVESTMENT CO., LTD. Director 0.00%
Shen,Jing-Jia Independent Director 0.00%
Wu,Jin-Cheng Independent Director 0.00%
Chen,Guo-Hua Independent Director 0.00%
營業項目
  • Manufacture of Drugs and Medicines(200211)
  • Manufacture of Cosmetics(193299)
  • Wholesale of Other Specialized Wholesale Not Elsewhere Classified(469999)
  • Manufacture of Other Medical Instruments and Supplies(332900)
  • 公司歷程
  • Change Person in Charge to Lin,Qi-Guo
    2021/10/19
  • Change Person in Charge to Lin,Xie-Jian
    2021/06/04
  • Change Person in Charge to Lin,Qi-Guo
    2019/10/28
  • Change Person in Charge to Cai,Guo-Zhou
    2016/07/13
  • Change Person in Charge to Jiang,Guo-Chuan
    2015/10/06
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2025 2024 2023
    Operating income 554,173 1,818,018 1,688,987
    Operating cost 113,321 339,352 284,097
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 440,852 1,478,666 1,404,890
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 440,852 1,478,666 1,404,890
    Operating expenses 135,242 551,702 510,095
    Other gain (loss), net - - -
    Operating profit (loss) 305,610 926,964 894,795
    Non-operating income and expenses 8,749 26,314 14,597
    Net profit (loss) before tax 314,359 953,278 909,392
    Income tax expense (benefits) 91,041 273,873 283,684
    Net profit (loss) of ongoing business for the current period 223,318 679,405 625,708
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period 223,318 679,405 625,708
    Other comprehensive profit (loss), net 4,496 6,480 -7,541
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period 227,814 685,885 618,167
    Net profit (loss) attributable to owners of parent company 223,318 679,405 625,708
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company 227,814 685,885 618,167
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 4 12 11
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities 273,697 561,035 848,556
    Net cash inflows (outflows) from investing activities 40,680 -21,939 -16,036
    Net cash inflow (outflow) from financing activities -8,116 -626,110 -549,798
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 5,601 7,785 -17,328
    Increase (decrease) in cash and cash equivalents in the current period 311,862 -79,229 265,394
    Beginning balance of cash and cash equivalents 775,465 854,694 589,300
    Ending balance of cash and cash equivalents 1,087,327 775,465 854,694
    項目 2025 2024 2023
    Current asset 1,319,826 1,092,512 1,078,938
    Non-current asset 986,264 1,002,460 1,080,094
    Total asset 2,306,090 2,094,972 2,159,032
    Current liability 995,847 328,912 457,433
    Non-current liability 201,362 253,222 275,553
    Total liability 1,197,209 582,134 732,986
    share capital 544,630 544,630 544,630
    Equity - secruity token - - -
    capital reserve 3,651 3,651 3,651
    retained earning 564,659 973,112 892,800
    Other equity -4,059 -8,555 -15,035
    Treasury stock - - -
    Total equity attributable to owners of parent company 1,108,881 1,512,838 1,426,046
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 1,108,881 1,512,838 1,426,046
    Share capital awaiting retirement (unit: share) - - -
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 20 27 26
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • SUNMAX
  • Deusaderm
  • FACIAL GAIN
  • 膚萊美
  • 膚漾美
  • RenovaGen
  • 膚泉原
  • 膚久美
  • FULLSGEN
  • 双美
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Pay severance pay, etc.
    2023
  • Revocation of resolutions of shareholders' meeting, etc.
    2020
  • Confirmation that the resolution of the board of directors is invalid
    2019
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。